Novo Lifts 2026 Outlook as Q3 Sales and Profit Beat, Wegovy Pill Sets Launch Record
NVO sits 22% above its 52-week low of $35.12.
Summary
Novo Nordisk beat on both lines and raised guidance: Q3 sales of $11.90 billion (79.195 billion kroner) topped the $11.39 billion consensus, and adjusted EPS of 87 cents cleared the 81-cent estimate. Adjusted operating profit rose 27% at CER to 31.720 billion kroner, helped by GLP-1 growth and lower transformation costs versus the roughly 9 billion kroner booked a year earlier. The growth engine is obesity, up 22% at CER to 26.146 billion kroner, with the Wegovy pill generating 5.394 billion kroner in sales, up 53% from the prior quarter and ahead of the 4.62 billion kroner consensus. Diabetes remains the drag: sales fell 5% at CER to 47.545 billion kroner, with U.S. GLP-1 diabetes down 10% on lower volumes and wholesaler inventory shifts, and injectable Ozempic off 11%. Management now guides 2026 adjusted sales and operating profit growth of -2% to +2% at CER, versus the prior forecast of declines up to 6%, and lifted free cash flow guidance to DKK 60-70 billion. The read-across is negative for Eli Lilly, which dominates injectables but now faces a credible oral competitor; CEO Mike Doustdar said Novo has held its ground since Lilly's rival pill launched.
At the time of this announcement, NVO was trading at $42.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $178.8B. The 52-week trading range was $35.12 to $64.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.